Additional file 1 of Effects of obesity on CC16 and their potential role in overweight/obese asthma

Additional file 1. Table S1. Frequency of the CC16 genetic polymorphism (rs3741240). Table S2. Characteristics of non-smoking patients with lung cancer without any pulmonary diseases by BMI group. Table S3. Characteristics of the participants who attended the hospital for routine health check-ups (population 1, n = 357). Table S4. Associations between characteristics and serum CC16 levels in participants who attended the hospital for routine health check-ups (population 1, n = 357). Table S5. Characteristics of the young healthy participants (population 2, n = 137). Table S6. Association between the characteristics of young healthy participants and plasma CC16 levels (population 2, n = 137). Table S7. Characteristics of patients with asthma (population 3, n = 206). Table S8. BMI distribution in patients with severe and non-severe asthma (population 3, n = 206). Table S9. Associations between characteristics and serum CC16 levels in patients with asthma (population 3, n = 206). Fig. S1. Circulating CC16 levels based on the CC16 genetic polymorphism (rs3741240). Fig. S2. Flowchart for conducting CC16, SCBB3A2, and MUC5AC immunohistochemistry in the cancer-free lung tissues of never smoking human participants. Fig. S3. Association of circulating CC16 levels and categorical BMI in the combination of three populations excluding current smokers. Fig. S4. Decreased SCGB3A2 expressing cells in the airways of obese mice and overweight/obese humans. Fig. S5. Comparison of serum CC16 levels and blood SP-A and SP-D levels in obese vs. control mice. Fig. S6. Association of circulatory CC16 with airway hyperresponsiveness in young healthy participants (population 2). Fig. S7. Reduced serum CC16 levels among severe compared to non-severe asthma patients (population 3). Fig. S8. Inverse association of circulatory CC16 and inhaled corticosteroid (ICS) dose in asthma patients (population 3). Fig. S9. Circulatory CC16 levels according to required ICS dose in asthma patients (population 3).